ERBB2 and breast carcinoma: To ensure patients benefit from NAC aimed at breast conservation, this study developed and validated a model based on clinicopathological characteristics, traditional MRI features, and radiomics features to predict tumor shrinkage patterns after NAC in HR+/HER2- breast cancer.